Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32
Alliance Global Partners analyst Matthew Venezia initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $32.
Share
Why It Matters
A professional stock expert says Immunome looks like a good buy. They picked a target price to help you see what they think it's worth.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.